Gastroparesis Symptoms: 8 Signs of Slow Stomach Emptying

Gastroparesis literally means "stomach paralysis." Your stomach still works, but the muscles that normally grind food into a pulp and shove it into the small intestine are firing too slowly, so meals sit for hours instead of leaving in the usual 90 to 120 minutes. The clinical bar is objective: more than 10% of a standardized test meal still in the stomach four hours after you ate it, on a gastric emptying scintigraphy scan (PMC 2017 diagnostic validation).

The condition has moved from a niche diagnosis to a mainstream concern in the last three years. Roughly 30 to 50% of people with long-standing diabetes develop delayed gastric emptying, and the surge in GLP-1 use has pushed "stomach paralysis" into general search trends. Here are the eight symptoms that actually matter, what causes them, and when the pattern warrants a workup.

What Gastroparesis Actually Is

The stomach isn't a passive bag. It's a muscular pump that grinds food (a process called trituration), mixes it with acid and enzymes, and pushes the resulting slurry (chyme) through the pylorus into the duodenum in coordinated waves. The pacemaker cells that time those waves are called interstitial cells of Cajal, and the coordination is run by the vagus nerve.

Gastroparesis happens when that system breaks down. The vagus nerve stops signaling properly, the interstitial cells decline in number, or the stomach's smooth muscle itself weakens. Motility drops, meals overstay, and the stomach becomes distended and irritable. The StatPearls chapter on gastroparesis notes that all three defects have been documented in biopsy studies of severe cases.

Critically, gastroparesis is a diagnosis of documented delayed emptying plus the absence of a mechanical block. A tumor, a stricture, or a large bezoar can produce the exact same symptom picture, and none of them get treated as gastroparesis. That's why an upper endoscopy usually comes before scintigraphy in the workup.

The 8 Core Symptoms

1. Nausea

The most common symptom by a wide margin. Data from the NIDDK Gastroparesis Clinical Research Consortium put nausea in roughly 90% of patients seen at referral centers. It's often worst in the late afternoon or evening because breakfast and lunch are still fermenting in the stomach when dinner arrives. Standard antiemetics like ondansetron help control the sensation but don't fix the underlying motility problem.

2. Vomiting Undigested Food

This is the symptom that separates gastroparesis from run-of-the-mill dyspepsia. Because food isn't leaving the stomach, patients sometimes vomit recognizable pieces of a meal eaten many hours or even a full day earlier. Roughly 84% of consortium patients reported vomiting as a primary complaint. When it happens after a normal-sized meal in the absence of any illness, that's a red flag worth mentioning to a doctor.

3. Early Satiety

Getting full after only a few bites. The stomach has less room because it's already partially full from the previous meal. Patients describe portions that used to feel small now being impossible to finish. Over time this drives caloric restriction and weight loss without any conscious intent.

4. Postprandial Fullness

The sensation that a meal is sitting like a rock in the upper abdomen an hour, two hours, four hours after eating. It's the symptom most closely tied to the underlying pathology - food really is still there. It's also the one that responds most quickly to a small-particle, low-fat diet.

5. Bloating and Visible Distension

Trapped gas plus retained food expands the upper abdomen. Unlike lower-GI bloating that eases with a bowel movement, gastroparesis bloating tracks with meals and doesn't respond to laxatives. Our guide to what causes bloating covers the broader differential, but the gastroparesis pattern is specifically postprandial, upper, and persistent.

6. Upper Abdominal Pain

Often underestimated. The NIDDK consortium data on idiopathic gastroparesis found that 72% of patients reported abdominal pain, and it was severe in about 42%. It's typically epigastric (just below the sternum), described as burning, gnawing, or a dull ache, and often mistaken for reflux or an ulcer for months before the motility question gets asked.

7. Unintentional Weight Loss

A direct consequence of early satiety, nausea, and food aversion. Malnutrition and micronutrient deficiencies are common enough that a Johns Hopkins-led study of consortium patients found the majority failed to meet the recommended daily intake for calories, iron, magnesium, potassium, zinc, and vitamins D, E, and K. Persistent weight loss with any of the symptoms above is a reason to move faster on evaluation.

8. Erratic Blood Sugar (in Diabetics)

This one is specific to diabetic gastroparesis and often the first clue. When food emptying is unpredictable, insulin dosed for a meal peaks at the wrong time. The result is postprandial hypoglycemia followed hours later by hyperglycemia as the delayed meal finally reaches the small intestine. Continuous glucose monitor tracings in undiagnosed diabetic gastroparesis are almost pathognomonic.

Who Gets Gastroparesis

Population-based data from Olmsted County, Minnesota (Mayo Clinic's reference cohort) put the age-adjusted prevalence at 37.8 per 100,000 women and 9.6 per 100,000 men (PMC review of gastroparesis epidemiology). The roughly 4:1 female skew shows up across idiopathic, diabetic, and postsurgical subtypes and has never been fully explained. Sex hormone influence on gastric motility is the leading hypothesis.

Among 401 patients enrolled in the NIDDK Gastroparesis Clinical Research Consortium, the etiology breakdown was:

• Idiopathic: 61% - no identifiable cause after full workup, often preceded by a viral gastroenteritis that never fully resolved
• Diabetic: Roughly 30% of the consortium cohort; population-wide, 30 to 50% of people with long-standing type 1 or type 2 diabetes have some degree of delayed emptying
• Postsurgical: Vagus nerve injury from fundoplication, bariatric surgery, or esophagectomy
• Postinfectious, medication-induced, connective tissue disease (scleroderma), and neurologic disorders (Parkinson's) fill out the rest

The GLP-1 Wrinkle

Semaglutide, tirzepatide, and other GLP-1 receptor agonists slow gastric emptying as their intended mechanism - that's what makes them work for weight loss. In most people, that slowing is dose-dependent and reversible. In a minority, it crosses into clinical gastroparesis.

A 2024 real-world analysis of the FDA Adverse Event Reporting System (FAERS) found that semaglutide had the broadest range of GI adverse effects among GLP-1s, including a specific signal for delayed gastric emptying. The FDA added "delayed gastric emptying" to the Ozempic label in 2023 and now states the drug is not recommended in patients with severe gastroparesis. The full breakdown of GLP-1 gut effects is covered in our Ozempic digestive side effects article.

The practical implication: if you started a GLP-1 and cannot titrate past a low dose because of persistent nausea, vomiting, or early satiety that doesn't fade over 4 to 6 weeks, you have a plausible case for a gastric emptying study rather than white-knuckling the escalation.

How It's Diagnosed

Step One: Rule Out Obstruction

Upper endoscopy first. A stricture, an ulcer, a mass, or a retained bezoar (a hardened mass of food and fiber) mimics gastroparesis exactly. Skipping endoscopy and starting motility drugs is a mistake because prokinetics do nothing for a mechanical block and can delay a cancer diagnosis.

Step Two: Gastric Emptying Scintigraphy (GES)

The reference standard. You eat a standardized low-fat meal (typically egg whites, toast, and jam) labeled with a small dose of technetium-99m. A gamma camera measures how much radioactivity remains in the stomach at 1, 2, 3, and 4 hours. Retention of more than 10% at 4 hours defines gastroparesis, and severity is graded by how much is left:

• Mild: 11 to 20% retention at 4 hours
• Moderate: 21 to 35%
• Severe: More than 35%

A four-hour scan matters. Older two-hour protocols missed a substantial fraction of cases and are no longer considered adequate. If your GI orders a two-hour study, ask why.

Alternatives

The ¹³C-spirulina breath test, cleared by the FDA in 2015, gives comparable accuracy without radiation and is useful in pregnancy, pediatrics, and repeated follow-up studies. Wireless motility capsules measure pressure and pH through the whole GI tract but are less commonly used as first-line.

Treatment: The Playbook

Diet First

The AGA Clinical Practice Guideline on Management of Gastroparesis and the ACG guidelines converge on the same first-line approach: modify what and how you eat before adding drugs.

• Small, frequent meals. Four to six per day instead of three. Smaller volumes empty faster.
• Low fat. Fat is the single strongest slower of gastric emptying. Solid fat especially. Fat-containing liquids like a milkshake are often tolerated because the liquid phase empties on a separate, faster track.
• Low insoluble fiber. Fiber is the ingredient that can clump into a bezoar. Skins, seeds, raw vegetables, and whole nuts are the offenders.
• Small particle size. Blend, chop, or mash. A Practical Gastroenterology review highlights small-particle diets as one of the few interventions with randomized evidence for symptom improvement.
• Stay upright for 1 to 2 hours after eating. Gravity helps.
• Chew thoroughly. The stomach's grinding work is partially offloaded by teeth.

Prokinetics

Metoclopramide is the only FDA-approved drug for gastroparesis. It's a dopamine antagonist that stimulates stomach contractions. Standard dose: 10 mg orally four times a day, 30 minutes before meals and at bedtime. The catch is a black-box warning for tardive dyskinesia, a movement disorder that can be permanent. That's why the FDA cap is 12 weeks of use and why lower doses and shorter courses are preferred.

Erythromycin, an antibiotic, is a potent motilin receptor agonist. It works quickly but tachyphylaxis (loss of effect) typically develops within 4 weeks, and it prolongs the QT interval. Useful short term, not for chronic management.

Prucalopride, a 5-HT4 agonist approved for chronic constipation, has shown improvement in gastric emptying and symptoms in two small four-week trials but is not FDA-approved for gastroparesis. The AGA guideline gave it a conditional recommendation against as first-line therapy.

Second-Line and Beyond

Gastric electrical stimulation (Enterra device), pyloric interventions such as G-POEM (gastric peroral endoscopic myotomy), botulinum toxin injection into the pylorus, and jejunostomy feeding tubes are options for severe, refractory disease. Cannabinoids and mirtazapine are sometimes used off-label for nausea and appetite. None of these are appropriate before a serious trial of diet and prokinetics.

When to See a Gastroenterologist

Any of these warrant a workup rather than another round of over-the-counter reflux drugs:

• Vomiting undigested food from hours-old meals
• Unintentional weight loss of more than 5% of body weight
• Postprandial fullness or early satiety that's been present for more than a month
• New erratic blood sugars in a person with diabetes on stable therapy
• Nausea and vomiting that persisted after a viral gastroenteritis
• Persistent nausea while on a GLP-1 that hasn't improved after 4 to 6 weeks

Our when to see a gastroenterologist guide walks through what to expect at the appointment and the tests that typically get ordered.

What Tracking Actually Adds

Gastroparesis is a diagnosis built on patterns, not one-off symptoms. A GI will ask when nausea starts relative to meals, how large a meal you can tolerate before early satiety kicks in, whether symptoms track with fat content, whether your bowel movements have slowed too, and (if diabetic) how your glucose responds to a fixed meal. Answering those from memory is unreliable.

Two weeks of logged data - what you ate, when, portion size, symptom onset and duration, stool form on the Bristol scale (our Bristol Stool Chart guide covers the seven types), and any medications - is enough to make the pattern obvious and to give the workup a head start. It's also what you'll want during a treatment trial, because "did the low-fat diet help" is almost impossible to answer from recall alone.